145 related articles for article (PubMed ID: 6324701)
21. Comparative study of Algicon versus Gaviscon in symptomatic gastro-oesophageal reflux.
Ward AE
Br J Clin Pract Suppl; 1989 Feb; 66():52-5; discussion 61-4. PubMed ID: 2556176
[No Abstract] [Full Text] [Related]
22. Antacid therapy--changes in mineral metabolism.
Herzog P; Holtermüller KH
Scand J Gastroenterol Suppl; 1982; 75():56-62. PubMed ID: 6293043
[TBL] [Abstract][Full Text] [Related]
23. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.
Wilkinson J; Wade A; Thomas SJ; Jenner B; Hodgkinson V; Coyle C
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):86-93. PubMed ID: 30272584
[TBL] [Abstract][Full Text] [Related]
24. Pyrogastrone treatment of peptic oesophagitis: analysis of 104 patients treated during a 3 1/2-year period.
Markham C; Reed PI
Scand J Gastroenterol Suppl; 1980; 65():73-82. PubMed ID: 6259715
[TBL] [Abstract][Full Text] [Related]
25. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms.
Coyle C; Crawford G; Wilkinson J; Thomas SJ; Bytzer P
Aliment Pharmacol Ther; 2017 Jun; 45(12):1524-1533. PubMed ID: 28464343
[TBL] [Abstract][Full Text] [Related]
26. Gastric pH and endoscopic appearance after Algicon administration.
Lambert JR; Korman MG; Nicholson L
Br J Clin Pract Suppl; 1989 Feb; 66():25-8; discussion 35-6. PubMed ID: 2511920
[No Abstract] [Full Text] [Related]
27. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerance of Algicon in patients with reflux oesophagitis.
Lancaster Smith MJ; Miller JP; Whorwell PJ
Br J Clin Pract Suppl; 1989 Feb; 66():38-42; discussion 61-4. PubMed ID: 2511921
[No Abstract] [Full Text] [Related]
29. [Gastroesophageal reflux. Results of a multicenter study of 170 patients on the therapeutic value of the Gaviscon drinkable suspension].
Chevrel B
Med Chir Dig; 1980; 9(6):535-9. PubMed ID: 6259459
[No Abstract] [Full Text] [Related]
30. A comparison between cisapride and Gaviscon with Carobel in the treatment of gastro-oesophageal reflux in infancy.
Greally P; Hampton FJ; MacFadyen UM; Simpson H
Ir Med J; 1992; 85(4 Suppl):14. PubMed ID: 1490841
[No Abstract] [Full Text] [Related]
31. Pyrogastrone for oesophagitis.
Drug Ther Bull; 1979 Aug; 17(16):63-4. PubMed ID: 228924
[No Abstract] [Full Text] [Related]
32. Effect of time of dosing relative to a meal on the raft formation of an anti-reflux agent.
Washington N; Greaves JL; Wilson CG
J Pharm Pharmacol; 1990 Jan; 42(1):50-3. PubMed ID: 1969950
[TBL] [Abstract][Full Text] [Related]
33. [Therapeutic procedures in gastroesophageal reflux disease].
Tytgat GN
Z Gastroenterol; 1986 Sep; 24 Suppl 2():40-4. PubMed ID: 2877526
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants.
Corvaglia L; Aceti A; Mariani E; De Giorgi M; Capretti MG; Faldella G
Aliment Pharmacol Ther; 2011 Feb; 33(4):466-70. PubMed ID: 21158879
[TBL] [Abstract][Full Text] [Related]
35. Oesophagitis and the role of antacid therapy.
Rhodes J
Scand J Gastroenterol Suppl; 1982; 75():74-6. PubMed ID: 6959253
[No Abstract] [Full Text] [Related]
36. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
[TBL] [Abstract][Full Text] [Related]
37. Gaviscon for gastro-oesophageal reflux in infants: a poorly effective treatment?
Cresi F; Savino F; Marinaccio C; Silvestro L
Arch Dis Child; 2006 Jan; 91(1):93. PubMed ID: 16371388
[No Abstract] [Full Text] [Related]
38. [Alginate-raft preparations in the treatment of acid reflux and heartburn (literature review)].
Mandel KG; Deggi BP; Brodi DA; Jeykobi GI
Eksp Klin Gastroenterol; 2008; (4):64-77. PubMed ID: 19145905
[No Abstract] [Full Text] [Related]
39. [pH gradient support and antacid action of gastroesophageal coating agents. In vitro pharmacologic study using a model of "the artificial stomach"].
Vatier J; Vitre MT; Vallot T; Mignon M
Gastroenterol Clin Biol; 1990; 14(5):414-22. PubMed ID: 2163935
[TBL] [Abstract][Full Text] [Related]
40. A comparative crossover study on the treatment of heartburn and epigastric pain: Liquid Gaviscon and a magnesium--aluminium antacid gel.
Chevrel B
J Int Med Res; 1980; 8(4):300-2. PubMed ID: 6250928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
